This story has been updated from a previous version which incorrectly characterized DNA Script's participation in the DNA Data Storage Alliance.
NEW YORK - Synthetic biology company DNA Script said on Tuesday that it has inked agreements with several distributors throughout the Asia-Pacific for its enzymatic DNA synthesis benchtop instrument.
"By increasing access, we give labs unparalleled opportunities to print the DNA they need, when they need it, to accelerate workflows across Sanger sequencing, RT-qPCR, NGS target enrichment, site-directed mutagenesis, CRISPR gene editing, gene assembly, FISH, and more," DNA Script CEO and Cofounder Thomas Ybert said in a statement.
The distribution deals are with Cold Spring Biotech for mainland China, Hong Kong, and Taiwan; Research Instruments for Singapore; Premas Life Sciences for India; and Bio-Medical Science for South Korea. Under the agreements, the distributors will provide sales and support for DNA Script's Syntax DNA printing system in labs throughout the Asia-Pacific region, the company said.
"The limiting factor for many molecular biology and genomic applications has been the ability to obtain synthetic DNA in a timely fashion," Cold Spring Biotech President Pasteur Tai said in a statement. "Because DNA Script's Syntax System provides on-site, benchtop oligo production, it will give labs new capabilities to accelerate their work."
Lauded by DNA Script as the world's "only commercial DNA manufacturing technology that utilizes the power of enzymatic DNA synthesis," the Syntax System received CE marking last November, clearing the way for its commercial sales in Europe. DNA Script also said it has deployed its Syntax platform to 41 academic, governmental, and commercial users through a targeted early-access program.
The French company, with locations in Paris and South San Francisco, California, completed its Series C financing in January with $200 million in new capital, adding to a $165 million dollar tranche announced last year.